Immunovant Inc

0.00 (0.00%)
6:37:28 PM EDT: $14.20 -0.16 (-1.11%)
Other Pre-Announcement

Immunovant Announces Imvt-1402, A Next Generation Anti-Fcrn

Published: 09/28/2022 14:57 GMT
Immunovant Inc (IMVT) - Immunovant Announces Imvt-1402, a Next Generation Anti-fcrn.
Immunovant Inc - Plan to Submit Ind and Initiate Phase 1 Study in Early 2023 With Initial Data Expected in Mid-2023.
Immunovant Inc - Previously Announced Programs for Lead Asset Batoclimab Continue at Full Speed.
Immunovant Inc - Cash Runway Guidance Into Calendar Year 2025 Remains Unchanged.
Immunovant Inc - Imvt-1402 is Also Expected to Have Composition of Matter Patent Protection Through at Least 2042, Assuming Issuance of Pending Patent.
Immunovant - in Animal Studies, Deep Igg Lowering Similar to Batoclimab With No Or Minimal Impact on Albumin and Low-density Lipoprotein Was Observed.